Posters

Photodynamic therapy vs panretinal photocoagulation treatment in patients with chronic central serous chorioretinopathy: about eight cases

Poster Details

First Author: F.Hjira MOROCCO

Co Author(s): A. Er-Radi   H. Tazi   B. Ouezzani   E. Abdallah   A. Berraho        

Abstract Details

Purpose:

To compare the anatomic and functional efficacy and safety of photodynamic therapy (PDT) versus Panretinal Photocoagulation treatment in patients with chronic central serous chorioretinopathy (cCSC)

Setting:

Open-label, monocentric, randomized controlled study about Eight Patients with cCSC whose disease had to be confirmed by both clinical characteristics and findings on multimodal imaging.

Methods:

We report eight central serous chorioretinopathy cases based on angiographic and OCT diagnosis. These cases were observed over a period of 2 years, Between November 2014 and September 2016. The primary end point was the complete disappearance of SRF at the first evaluation visit at 6 to 8 weeks after treatment. As a secondary outcome measure, we assessed this anatomic result at the final evaluation visit at 7 to 8 months after treatment. Other secondary outcomes covered functional improvement and included change in best-corrected visual acuity, and vision-related quality of life using a validated questionnaire

Results:

All the patients were females, between 30 and 50 years old.The reason for consultation was a variable decrease in visual acuity, a central scotoma, or metamorphopsia. A Fundus examination and OCT showed subretinal fluid. The angiography showed break points in ink spots in the majority of the cases.Four patients were assigned randomly to PDT, and four were assigned randomly to PRP treatment.  At their first evaluation visit, SRF had resolved in 51.2%. At their final evaluation visit, a significantly higher percentage of PDT-treated patients demonstrated no SRF (75% vs. 25%).Moreover, the PDT-treated patients showed a significantly higher increase in BCVA.

Conclusions:

PDT is superior PRP for treating cCSC, leading to a significantly higher proportion of patients with complete resolution of SRF and functional improvement.

Financial Disclosure:

None